semaglutide taken off shortage list Semaglutide follows rival GLP-1RA tirzepatide in making it off the FDA's shortage list - Compoundedsemaglutidewith B12 semaglutide is removed from the shortage list

Is compoundedsemaglutidegoing away The FDA semaglutide shortage situation has seen a significant development: semaglutide was taken off the shortage list. This marks a crucial turning point after an extended period where the demand for these popular GLP-1 medications, including Ozempic and Wegovy, far outstripped supply. As of February 21, 2025, the U.2025年4月16日—Eli Lilly's GLP-1RA was taken off the FDA shortage list in December 2024. Despite pharmacies largely having to stop making the drug in mid-March ...S. Food and Drug Administration (FDA) has officially removed semaglutide from its drug shortage list, indicating that current and projected demand can now be met.

For a considerable time, semaglutide and its competitor, tirzepatide (found in Mounjaro and Zepbound), had been grappling with substantial shortages.Declaratory Order: Resolution of Shortages of Semaglutide ... These medications, primarily used for managing type 2 diabetes and aiding in weight loss, were first added to the FDA's shortage list around March 2022. The prolonged scarcity led to widespread concern among patients and healthcare providers, and also fueled the market for compounded semaglutide.2025年2月21日—Hims has told investors that even whensemaglutide is removed from the shortage list, it can still legally offer compounded treatments by ...

The removal of semaglutide from the shortage list on February 21, 2025, signifies that the supply chain issues that plagued the drug for years have been resolved. The FDA's determination suggests that drug manufacturer Novo Nordisk, the maker of Ozempic and Wegovy, has ramped up production to meet current and future demand. This brings welcome news to many who have struggled to access these treatments.

However, this resolution has also brought about changes, particularly concerning compounded semaglutide. For a period, when the branded versions faced shortages, pharmacies were permitted to compound semaglutide, often with additional ingredients like compounded semaglutide with B12, to help bridge the gap in availability.Ozempic and Wegovy are no longer in shortage, FDA says With semaglutide removed from the shortage list, the regulatory landscape for these compounded versions is shiftingFDA declares semaglutide shortage over, spelling end to .... Some reports indicate that compounders may have a limited grace period, typically 60 to 90 days, to phase out sales of compounded versions that mimic the branded drugs.The FDA has removed semaglutide injection products ... This raises questions about whether compounded semaglutide is FDA-approved or if compounded semaglutide is going away. The FDA's stance has been to clarify policies for compounders, and the implications for compounded semaglutide accessibility are significant.

The resolution of the semaglutide shortage on Feb 21, 2025, provides a clearer path forward for patients relying on these medications.2025年2月25日—The Reuters story, “Novo's Wegovy and Ozempicremoved fromUS FDAshortage list, compounders on notice” was picked up by a lot of news ... While the immediate shortages are over, the focus is now shifting towards the long-term implications for access, cost, and the role of compounded semaglutide. Patients experiencing shortages or seeking clarification on their treatment should consult with their healthcare provider to understand the best approach moving forwardOzempic and Wegovy are no longer in shortage, FDA says. The fact that semaglutide is no longer listed on the FDA website as being in shortage is a testament to the improving supply dynamics within the pharmaceutical industry. Healthcare professionals and patients can now expect that semaglutide injections from drug manufacturer Novo Nordisk are no longer in shortage, and that semaglutide is removed from the shortage list. This also means that semaglutide follows rival GLP-1RA tirzepatide in making it off the FDA's shortage list. Notably, Eli Lilly's GLP-1RA was taken off the FDA shortage list in December 2024, preceding semaglutide. These developments suggest a broader easing of supply constraints for GLP-1 medications.

It's important to note that while semaglutide and tirzepatide have been removed from the FDA's drug shortage list, there have been differing perspectives. For instance, one lawsuit alleges that supply issues for Ozempic and Wegovy still remain, highlighting the complexity of the situation.2025年2月27日—The FDA announced that theshortageofsemaglutide(Wegovy, Ozempic; Novo Nordisk) is resolved and now meets or exceeds both current and projected US demands. Nevertheless, the official declaration from the FDA marks a significant milestone.FDA Ends Semaglutide Shortage Listing, Contributing to ... The shortages of these drugs, which have been on the FDA's medication shortage list since 2022 due to extremely high patient demand, are now officially over.

In conclusion, semaglutide was officially declared to no longer be on shortage by the FDA on February 21, 2025. This marks the end of a challenging period characterized by supply constraints.FDA clarifies policies for compounders as national GLP-1 ... While the primary semaglutide products are now widely available, the era of readily accessible compounded semaglutide may be concluding, necessitating a re-evaluation of treatment strategies for many patients. The FDA's move signifies that semaglutide injection products (GLP-1) are now considered available, influencing how these vital medications are obtained and utilized.The GLP-1 drug shortage is over. What's next for ...